Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01594255 | CAEB071 Thorough QTc Study in Healthy Volunteers | PHASE1 | COMPLETED | 100 | — | — | Jul 1, 2009 | - | May 9, 2012 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| AEB071 300 mg | EXPERIMENTAL | - |
| AEB071 900 mg | EXPERIMENTAL | - |
| Placebo to AEB071 | PLACEBO_COMPARATOR | - |
| Moxifloxacin | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| sotrastaurin | DRUG | - |
| placebo to sotrastaurin | DRUG | - |
| Avelox | DRUG | - |
Inclusion Criteria: * Healthy male and female subjects age 18 to 50 years (including both) of age included, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening. Exclusion Criteria: * Smokers and tobacco ...